Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles

Abstract

Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) nucleotide-based therapeutics which are capable of targeting DNA and RNA as well as other biomolecules. ONs can be subdivided into several classes based on their chemical modifications and on the mechanisms of their target interactions. Historically, the largest hindrance to the widespread usage of ON therapeutics has been their inability to effectively internalize into cells and escape from endosomes to reach their molecular targets in the cytosol or nucleus. While cell uptake has been improved, “endosomal escape” remains a significant problem. There are a range of approaches to overcome this, and in this review, we focus on three: altering the chemical structure of the ONs, formulating synthetic, lipid-based nanoparticles to encapsulate the ONs, or biologically loading the ONs into extracellular vesicles. This review provides a background to the design and mode of action of existing FDA-approved ONs. It presents the most common ON classifications and chemical modifications from a fundamental scientific perspective and provides a roadmap of the cellular uptake pathways by which ONs are trafficked. Finally, this review delves into each of the above-mentioned approaches to ON delivery, highlighting the scientific principles behind each and covering recent advances.

Optimised Electroporation for Loading of Extracellular Vesicles with Doxorubicin

“…Given the intrinsic cell targeting capability and inherent biocompatibility, EVs serve as a promising drug-delivering platform that can mediate effective transport targeting specific tissues and cells [6,11,12,54]. In this study, we systematically optimised an established electroporation protocol, improving loading efficiency, recovery, and drug potency in vitro, accomplishing a 190-fold increased drug potency compared to naked doxorubicin, and twice the potency of lipodox, a liposomal form of doxorubicin.…”

Nanoligomers Targeting Human miRNA for the Treatment of Severe COVID-19 Are Safe and Nontoxic in Mice

“… 26 , 27 The use of polyethylene glycol resulted in issues with immune response and inhibited cellular uptake. 26 , 27 siRNA can independently elevate the innate immune response as well, 28 , 29 with success in avoiding this seen in only some platforms. 30 , 31 …”

Bioorthogonal regulation of DNA circuits for smart intracellular microRNA imaging

“…Liposomes represent a promising carrier for effectively delivering therapeutic agents. 44 An increased fluorescence intensity was shown in the tumor sites that were treated with the bioorthogonal APE1-regulated HCR system (group a, Fig. 5B ).…”